Ashish Sarraju
@AshishSarraju
Followers
638
Following
1K
Media
16
Statuses
224
Cardiologist @ClevelandClinic @CleClinicHVTI | Alum @StanCVFellows @Stanfordmedres | Preventive Cardiology, Trials, Digital Health | tweets own opinions
Cleveland, OH
Joined May 2017
Welcome to @khurramn1, who is now serving as Editor-in-Chief of @AJPCardio! Thank you to @ErinMichos & @DrNathanWong for their outstanding leadership. Make sure to read the latest issue🫀 https://t.co/xY5t1qJkQs #PreventiveCardiology #ASPC #AJPC
15
23
102
Join the most impactful board you’ll ever be on! ASPC is accepting nominations for 4 At-Large Board Members & 1 Secretary. Active members only. Deadline: Feb 13, 2026 Details: https://t.co/aYJVxX1zOy Apply: contact@aspconline.org @DrMichaelShapir @a_l_bailey @DrMarthaGulati
1
14
28
Honored to begin this week at @CleClinicHVTI leading new initiatives in CV genomics as: • Section Head, Haslam-Bailey Family Section of CV Genomics & Precision Medicine • Director, Center for CV Genomics & Data Sciences • William E. Macaulay Endowed Chair
3
11
74
Carotid web? Novel agents for stroke prevention? Interesting case discussions? We got it all covered at @CleClinicMD Cerebrovascular Center Innovations in Cerebrovascular Care Conference 2025! https://t.co/s7QAB8izm5 Thank you to our presenters @MariaSokolaMD @AshishSarraju
1
5
17
Atherosclerotic cardiovascular disease contributes substantially to the global burden of cardiovascular disease. A new trial suggests promise for broadening the therapeutic landscape for patients with pre-existing or high risk for ASCVD. Find out more: https://t.co/19tZYIqeLu
2
22
98
The BROADWAY trial assesses the safety and efficacy of obicetrapib among patients at high risk for cardiovascular events. Get more details ➡️ https://t.co/GPfRBQpxq6
#CardioX
acc.org
0
8
16
Lowering your LDL cholesterol can be crucial for managing heart disease. A new drug combination lowered it by nearly half in a new clinical trial. @AshishSarraju explains the findings. Read more: https://t.co/nTyB0Dgeyu
2
4
15
The results of the TANDEM trial have been published in The Lancet @TheLancet, simultaneously with their presentation at the #EASCongress2025! Read the full article here: https://t.co/mbFI1FHFNk
@AshishSarraju @ProfSNicholls @JohnKastelein @EASCongress @society_eas
0
4
17
Congratulations to my friend and colleague, @AshishSarraju , and the team at C5Research (@CleClinicHVTI ) on completing and publishing the TANDEM trial demonstrating the lipid lowering efficacy of obicetrapib-ezetimibe FDC
1
5
34
🚨Breaking news from #EASCongress2025 🚨 Obicetrapib/ezetimibe combo therapy nearly halved LDL at 84 days for patients with ASCVD or at high risk for it already taking maximally tolerated lipid-lowering therapy. @EASCongress @AshishSarraju #cardiology
https://t.co/FwyWP3boGM
healio.com
Obicetrapib plus ezetimibe combination therapy nearly halved LDL for patients with atherosclerotic heart disease or at high risk for it already taking maximally tolerated lipid-lowering therapy,...
0
3
6
And a randomized trial @TheLancet with this CETP drug and ezetimibe combination https://t.co/RknmvACftV
2
13
35
Two late-breaker clinical trials on Obicetrapib presented today at @EASCongress. 1st, by Steven Nissen. Note that this study evaluates a fixed-dose combination of obicetrapib/ezetimibe in pts treated with maximally tolerated doses of statins. #EASCongress2025 @JohnKastelein
1
5
17
Exciting day with more obicetrapib data for at @society_eas with publications in @NEJM and @TheLancet @JohnKastelein @ProfKausikRay @mdavidsonmd @ajnelson @julie_butters @MonashVHI @NewAmsPharma
3
27
115
1/ Now in @JACCJournals: The Coming AI Revolution in Clinical Trials. @euanashley @drnigam @AshishSarraju @kevin_schulman @HeartBobH @TheMahaf
https://t.co/fv3m9p0HMF
#JACC @StanfordMed @StanfordDeptMed @SCCR_Stanford
1
8
19
1/n We are excited to announce EchoPrime – the first echocardiography AI model capable of evaluating a full transthoracic echocardiogram study, identify the most relevant videos, and produce a comprehensive interpretation! Great work lead by @milos_ai, EchoPrime is the largest
30
163
485
Grateful to Jennifer sharing her journey with the diagnosis of FH. More work awaits to improve awareness, diagnosis, and management. Resources from the @FamilyHeartFdn are invaluable! #FHawarenessday @joshuawknowles @FaRodriguezMD @CleClinicHVTI @tavrkapadia
Jennifer's LDL cholesterol was more than three times the normal range. It's known as "bad" cholesterol because it can block arteries in the heart. Jennifer has a genetic condition called FH. Now she's using her diagnosis to help others. #FHAwarenessDay
https://t.co/6kqkDFkBoK
0
0
11
Jennifer's LDL cholesterol was more than three times the normal range. It's known as "bad" cholesterol because it can block arteries in the heart. Jennifer has a genetic condition called FH. Now she's using her diagnosis to help others. #FHAwarenessDay
https://t.co/6kqkDFkBoK
my.clevelandclinic.org
Jennifer's cholesterol was three times the normal range because of a condition called familial hypercholesterolemia.
0
5
8
Aspirin for primary prevention of cardiovascular disease has been shown to cause more bleeding than benefit in randomized trials over the past 5 years. But it's still being taken by 1 of 3 older Americans. https://t.co/m0u46RKekc
@AnnalsofIM @MohakGuptaMD @AshishSarraju
37
408
1K
.@AshishSarraju & S. Nissen discuss the evidence surrounding atherosclerotic plaque stabilization & regression as important clinical surrogates, and advancing therapeutic development https://t.co/QIrPpBgQ3h
@NatRevCardiol
5
24
108
Hot off the press! @AshishSarraju & Steven Nissen review the clinical evidence for atherosclerotic plaque stabilization and regression: https://t.co/UsBpo8x8Qp
@CleClinicHVTI
1
17
50